Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
Conditions
Brief summary
This study evaluates the efficacy and safety of penpulimab plus lenalidomide, rituximab, gemcitabine and oxaliplatin (R2-GemOx) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL). All patients will receive six cycles of penpulimab plus R2-GemOx. Afterwards, 1) patients who achieve complete response (CR)/unconfirmed (CRu)/partial response (PR) assessed by positron emission tomography/computedtomography (PET-CT) and are eligible for autologous stem cell transplantation (ASCT) will undergo ASCT. 2) Patients who achieve CR/CRu/PR assessed by PET-CT and are not eligible for ASCT will directly receive penpulimab and lenalidomide as maintenance treatment, penpulimab for a maximum of 6 months, lenalidomide monotherapy for 18 months. 3) Patients achieved stable disease (SD) or progression disease (PD) assessed by PET-CT will withdraw from this study and receive proper treatment based on investigator's decision.
Interventions
DRUGpenpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
Patients receive penpulimab+R2-GemOx two weeks for a cycle, detailed as follows: Combination therapy Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), for 6 cycles. R2-GemOx: lenalidomide 10 mg，d1-7; Rituximab 375mg/m2, d0; Gemcitabine 1000mg, d1; Oxaliplatin 100mg/m2, d1; every 2 weeks for a cycle, 6 cycles as protocol specified. Maintenance treatment: Combination of two drugs: * Anti-PD-1 antibody (penpulimab): Fixed dose of 200 mg every 2 weeks, d0, intravenous drip (without pretreatment), , for 6 months * lenalidomide: 10 mg, po, for 18 months.
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically confirmed CD20+ diffuse large B-cell lymphoma * Age range from 18 to 80 years; * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; * Expectation survival time over 3 months; * According to Lugano 2014, at least one measurable nodular lesion with a length of greater than 15 mm, or extranodal lesion greater than 10 mm, lesion on FDG-PET scan demonstrates uptake); * Diffuse large B-cell lymphoma patients failed to first-line rituximab based chemotherapy including anthracycline or anthracycline * Patients are allowed to receive palliative radiotherapy, but the last time radiotherapy cannot be within 7 days before the first study drug administration; * Adequate organ function * Willingness to provide written informed consent.
Exclusion criteria
* Pregnant or lactating women; * Subjects with a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 12 months; * Patients with autoimmune diseases requiring treatment or with a history of syndrome requiring systemic use of steroid immunosuppressive agents, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis, hyperthyroidism, hypothyroidism, etc; * Patients received systemic glucocorticoid therapy (excluding nasal spray, inhaled or other topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first administration; * Uncontrolled heart disease, including unstable angina pectoris, acute myocardial infarction 6 months before randomization, congestive heart failure (NYHA) heart function grade III or IV; or left ventricular ejection fraction of the heart \<50% ； * Patients are allergic to penpulimab, lenalidomide, CD20 monoclonal antibody and GemOx regimen * Patients who have had previous organ transplants (except autologous hematopoietic stem cell transplants); * History of other malignancy within the past 5 years (except for 1. basal cell carcinoma of the skin and 2. carcinoma in situ of the cervix and 3. patients who had received treatment for the purpose of cure and had not developed a malignant tumor with a known active disease in the previous 5 years); * Those who have had neurotoxicity of grade 3 or above within two weeks before treatment; * Severe or uncontrolled infections; * Patients with drug abuse, medical, psychological or social conditions that may interfere with the study results or the assessment of the study results; * Patients are unsuitable for the enrollment according to investigator's judgement.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete response rate | 6 weeks after the last dose of the combination therapy (each cycle is 14 days) | Complete response rate after treated by penpulimab and R2-GemOx |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 2 years | from date of inclusion to date of death from any cause |
| Progression-free survival（PFS） | 2 years | from date of inclusion to date of progression, relapse, or death from any cause |
| Rate of grade 3 or 4 treatment related adverse effect | Up to 30 days after the last cycle of per-protocol treatment and 90 days after last dose of anti-PD-1 antibody | All the adverse events of the patients related will be assessed and graded by NCI CTCAE v 5.0 |
Countries
China
Contacts
Primary ContactLi Wang, M.D., Ph.D
Backup ContactWei Xu, M.D., Ph.D
Outcome results
None listed